Inhibikase Therapeutics IKT reported its Q2 earnings results on Friday, August 12, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Inhibikase Therapeutics beat estimated earnings by 5.26%, reporting an EPS of $-0.18 versus an estimate of $-0.19.
Revenue was down $1.36 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.01 which was followed by a 1.63% increase in the share price the next day.
Here's a look at Inhibikase Therapeutics's past performance:
|Quarter||Q1 2022||Q4 2021||Q3 2021||Q2 2021|
To track all earnings releases for Inhibikase Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.